A novel high-throughput cell-based assay aimed at identifying inhibitors of DNA metabolism in bacteria

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 12, 2014, Pages 7264-7272

  Fan, Jun ^a   De Jonge, Boudewijn L M ^a   MacCormack, Kathy ^a   Sriram, Shubha ^a   McLaughlin, Robert E ^a   Plant, Helen ^a   Preston, Marian ^a   Fleming, Paul R ^a   Albert, Robert ^a   Foulk, Melinda ^a   Mills, Scott D ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CHLORHEXIDINE; DNA TOPOISOMERASE (ATP HYDROLYSING); GREEN FLUORESCENT PROTEIN; HYDROGEN PEROXIDE; INHIBITOR OF DNA METABOLISM; LINEZOLID; MEROPENEM; MITOMYCIN; NALIDIXIC ACID; NORFLOXACIN; NOVOBIOCIN; POLYMYXIN B; PSEUDOMONIC ACID; RECA PROTEIN; RIFAMPICIN; TETRACYCLINE; TRICLOSAN; TRIMETHOPRIM; UNCLASSIFIED DRUG; BACTERIAL DNA; CARRIER PROTEIN; ESCHERICHIA COLI PROTEIN; HYBRID PROTEIN; MOLECULAR LIBRARY; NUCLEIC ACID SYNTHESIS INHIBITOR; OUTER MEMBRANE PROTEIN; TOLC PROTEIN, E COLI;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM; BACTERIUM MUTANT; BIOSENSOR; CELL ASSAY; CONTROLLED STUDY; DNA METABOLISM; DNA REPAIR; ENZYME ACTIVITY; ESCHERICHIA COLI; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; IC50; LABORATORY; NONHUMAN; PEPTIDE LIBRARY; PLASMID; REPORTER GENE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DEFICIENCY; DRUG EFFECTS; GENETIC PROCEDURES; GENETICS; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; PROMOTER REGION;

BACTERIAL OUTER MEMBRANE PROTEINS; BIOSENSING TECHNIQUES; DNA GYRASE; DNA, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; GENE EXPRESSION; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HIGH-THROUGHPUT SCREENING ASSAYS; INHIBITORY CONCENTRATION 50; MEMBRANE TRANSPORT PROTEINS; NUCLEIC ACID SYNTHESIS INHIBITORS; PLASMIDS; PROMOTER REGIONS, GENETIC; REC A RECOMBINASES; RECOMBINANT FUSION PROTEINS; SMALL MOLECULE LIBRARIES; SOS RESPONSE (GENETICS);

EID: 84912571892     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03475-14     Document Type: Article

References (53)

1. Rice LB. 2008. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J. Infect. Dis. 197:1079-1081. http: //dx.doi.org/10.1086/533452.
2. Spellberg BR, Gilbert GD, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards J. 2008. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46:155-164. http://dx.doi.org/10.1086 /524891.
3. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert GD, Rice LB, Scheld WM, Spellberg B, Bartlett JG. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12. http://dx.doi.org/10.1086/595011.
4. Rex JH, Eisenstein BI, Alder J, Goldberger M, Meyer R, Dane A, Friedland I, Knirsch C, Sanhai WR, Tomayko J, Lancaster C, Jackson J. 2013. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect. Dis. 3:269-275. http://dx .doi.org/10.1016/S1473-3099(12)70293-1.
5. Silver LL. 2011. Challenges of antibacterial discovery. Clin. Microbiol. Rev. 24:71-109. http://dx.doi.org/10.1128/CMR.00030-10.
6. Payne DJ, Gwynn MN, Holmes DJ, Pompliano D. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6:29-40. http://dx.doi.org/10.1038/nrd2201.
7. Monaghan RL, Barrett JF. 2006. Antibacterial drug discovery-then, now and the genomics future. Biochem. Pharmacol. 71:901-909. http://dx.doi .org/10.1016/j.bcp.2005.11.023.
8. Sanyal G, Doig P. 2012. Bacterial DNA replication enzymes as targets for antibacterial drug discovery. Expert Opin. Drug Discov. 7:327-339. http: //dx.doi.org/10.1517/17460441.2012.660478.
9. Wolfson JS, Hooper DC. 1985. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob. Agents Chemother. 28:581-586. http://dx.doi.org/10.1128/AAC.28 .4.581.
10. Miller AA, Bundy GL, Mott JE, Skepner JE, Boyle TP, Harris DW, Hromockyj AE, Marotti KR, Zurenko GE, Munzner JB, Sweeney MT, Bammert GF, Hamel JC, Ford CW, Zhong WZ, Graber DR, Martin GE, Han F, Dolak LA, Seest EP, Ruble JC, Kamilar GM, Palmer JR, Banitt LS, Hurd AR, Barbachyn MR. 2008. Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors. Antimicrob. Agents Chemother. 52:2806-2812. http://dx.doi.org/10 .1128/AAC.00247-08.
11. Black MT, Stachyra T, Platel D, Girard AM, Claudon M, Bruneau JM, Miossec C. 2008. Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases. Antimicrob. Agents Chemother. 52:3339-3349. http://dx.doi.org/10.1128 /AAC.00496-08.
12. Grossman TH, Bartels DJ, Mullin S, Gross CH, Parsons JD, Liao Y, Grillot AL, Stamos D, Olson ER, Charifson PS, Mani N. 2007. Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds. Antimicrob. Agents Chemother. 51:657-666. http: //dx.doi.org/10.1128/AAC.00596-06.
13. Eakin AE, Green O, Hales N, Walkup GK, Bist S, Singh A, Mullen G, Bryant J, Embrey K, Gao N, Breeze A, Timms D, Andrews B, Uria- Nickelsen M, Demeritt J, Loch JT, Hull K, Blodgett A, Illingworth RN, Prince B, Boriack-Sjodin PA, Hauck S, MacPherson LJ, Ni H, Sherer B. 2012. Pyrrolamide DNA gyrase inhibitors: fragment-based nuclear magnetic resonance screening to identify antibacterial agents. Antimicrob. Agents Chemother. 56:1240-1246. http://dx.doi.org/10.1128/AAC.05485-11.
14. Keating TA, Newman JV, Olivier NB, Otterson LG, Andrews B, Boriack- Sjodin PA, Breen JN, Doig P, Dumas J, Gangl E, Green OM, Guler SY, Hentemann MF, Joseph-McCarthy D, Kawatkar S, Kutschke A, Loch JT, McKenzie AR, Pradeepan S, Prasad S, Martínez-Botella G. 2012. In vivo validation of thymidylate kinase (TMK) with a rationallydesigned, selective antibacterial compound. Am. Chem. Soc. Chem. Biol. 7:1866-1872. http://dx.doi.org/10.1021/cb300316n.
15. Mills SD, Eakin AE, Buurman ET, Newman JV, Gao N, Huynh H, Johnson KD, Lahiri S, Shapiro AB, Walkup GK, Yang W, Stokes SS. 2011. Novel bacterial NAD-dependent DNA ligase inhibitors with broad-spectrum activity and antibacterial efficacy in vivo. Antimicrob. Agents Chemother. 55: 1088-1096. http://dx.doi.org/10.1128/AAC.01181-10.
16. Alt S, Mitchenall LA, Maxwell A, Heide L. 2011. Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics. J. Antimicrob. Chemother. 66: 2061-2069. http://dx.doi.org/10.1093/jac/dkr247.
17. Urban A, Eckermann S, Fast B, Metzger S, Gehling M, Ziegelbauer K, Rubsamen-Waigmann H, Freiberg C. 2007. Novel whole-cell antibiotic biosensors for compound discovery. Appl. Environ. Microbiol. 73:6436-6443. http://dx.doi.org/10.1128/AEM.00586-07.
18. Norman A, Hestbjerg Hansen L, Sørensen SJ. 2005. Construction of a ColD cda promoter-based SOS-green fluorescent protein whole-cell biosensor with higher sensitivity toward genotoxic compounds than constructs based on recA, umuDC, or sulA promoters. Appl. Environ. Microbiol. 71:2338-2346. http://dx.doi.org/10.1128/AEM.71.5.2338-2346.2005.
19. Shapiro E, Baneyx F. 2007. Stress-activated bioluminescent Escherichia coli sensors for antimicrobial agents detection. J. Biotechnol. 132:487-493. http://dx.doi.org/10.1016/j.jbiotec.2007.08.021.
20. Yagi K. 2007. Applications of whole-cell bacterial sensors in biotechnology and environmental science. Appl. Microbiol. Biotechnol. 73:1251-1258. http://dx.doi.org/10.1007/s00253-006-0718-6.
21. Mills SD, Dougherty TJ. 2011. Cell-based screening in antibacterial discovery, p 901-930. In Dougherty T, Pucci MJ (ed), Handbook of antibiotic discovery and development, 1st ed, vol 2 Springer, New York, NY.
22. Sutton MD, Smith BT, Godoy VG, Walker GC. 2000. The SOS response: recent insights into umuDC-dependent mutagenesis and DNA damage tolerance. Annu. Rev. Genet. 34:479-497. http://dx.doi.org/10.1146 /annurev.genet.34.1.479.
23. Brent R, Ptashne M. 1981. Mechanism of action of the lexA gene product. Proc. Natl. Acad. Sci. U. S. A. 78:4204-4208. http://dx.doi.org/10.1073 /pnas.78.7.4204.
24. Craig NL, Roberts JW. 1981. Function of nucleoside triphosphate and polynucleotide in Escherichia coli recA protein directed cleavage of phage lambda repressor. J. Biol. Chem. 256:8039-8044.
25. Little JW. 1991. Mechanism of specific LexA cleavage: autodigestion and the role of RecA coprotease. Biochimie 73:411-421. http://dx.doi.org/10 .1016/0300-9084(91)90108-D.
26. Tsien RY. 1998. The green fluorescent protein. Annu. Rev. Biochem. 67:509-544.
27. Zhang R, Lin Y. 2009. DEG 5.0, a database of essential genes in both prokaryotes and eukaryotes. Nucleic Acids Res. 37:D455-D458. http://dx .doi.org/10.1093/nar/gkn858.
28. Hutter B, Fischer C, Jacobi A, Schaab C, Loferer H. 2004. Panel of Bacillus subtilis reporter strains indicative of various modes of action. Antimicrob. Agents Chemother. 48:2588-2594. http://dx.doi.org/10.1128 /AAC.48.7.2588-2594.2004.
29. Shapiro E, Baneyx F. 2002. Stress-based identification and classification of antibacterial agents: second-generation Escherichia coli reporter strains and optimization of detection. Antimicrob. Agents Chemother. 46:2490-2497. http://dx.doi.org/10.1128/AAC.46.8.2490-2497.2002.
30. Koronakis V, Eswaran J, Hughes C. 2004. Structure and function of TolC: the bacterial exit duct for proteins and drugs. Annu. Rev. Biochem. 73:467-489. http://dx.doi.org/10.1146/annurev.biochem.73.011303.074104.
31. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, Datsenko KA, Tomita M, Wanner BL, Mori H. 2006. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio Collection. Mol. Syst. Biol. 2:1-11. http://dx.doi.org/10.1038/msb4100050.
32. Cormack BP, Valdivia RH, Falkow S. 1996. FACS-optimized mutants of the green fluorescent protein (GFP). Gene 173:33-38. http://dx.doi.org /10.1016/0378-1119(95)00685-0.
33. Zaslaver A, Bren A, Ronen M, Itzkovitz S, Kikoin I, Shavit S, Liebermeister W, Surette MG, Alon U. 2006. A comprehensive library of fluorescent transcriptional reporters for Escherichia coli. Nat. Methods 3:623-628. http://dx.doi.org/10.1038/nmeth895.
34. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. M07-A8, vol 29, no. 2 Clinical and Laboratory Standards Institute, Wayne, PA.
35. de Jonge BLM, Walkup GK, Lahiri SD, Huynh H, Neckermann G, Utley L, Nash TJ, Brock J, San Martin M, Kutschke A, Johnstone M, Laganas V, Hajec L, Gu R, Ni H, Chen B, Hutchings K, Holt E, McKinney D, Gao N, Livchak S, Thresher J. 2013. Discovery of inhibitors of 4=- phosphopantetheine adenylyltransferase (PPAT) to validate PPAT as a target for antibacterial therapy. Antimicrob. Agents Chemother. 57:6005-6015. http://dx.doi.org/10.1128/AAC.01661-13.
36. Shapiro AB, Walkup GK, Keating TA. 2009. Correction for interference by test samples in high-throughput assays. J. Biomol. Screen. 14:1008-1016. http://dx.doi.org/10.1177/1087057109341768.
37. Buurman ET, Johnson KD, Kelly RK, MacCormack K. 2006. Different modes of action of naphthyridones in gram-positive and gram-negative bacteria. Antimicrob. Agents Chemother. 50:385-387. http://dx.doi.org /10.1128/AAC.50.1.385-387.2006.
38. Hunt DE, Sandham HJ. 1969. Improved agar gradient-plate technique. Appl. Microbiol. 17:329-330.
39. Reck F, Alm RA, Brassil P, Newman JV, Ciaccio P, McNulty J, Barthlow H, Goteti K, Breen J, Comita-Prevoir J, Cronin M, Ehmann DE, Geng B, Godfrey AA, Fisher SL. 2012. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pKa: antibacterial agents with an improved safety profile. J. Med. Chem. 55:6916-6933. http://dx.doi.org/10.1021/jm300690s.
40. Manchester JI, Dussault DD, Rose JA, Boriack-Sjodin PA, Uria- Nickelsen M, Ioannidis G, Bist S, Fleming P, Hull KG. 2012. Discovery of a novel azaindole class of antibacterial agents targeting the ATPase domains of DNA gyrase and topoisomerase IV. Bioorg. Med. Chem. Lett. 22:5150-5156. http://dx.doi.org/10.1016/j.bmcl.2012.05.128.
41. Uria-Nickelsen M, Neckermann G, Sriram S, Andrews B, Manchester JI, Carcanague D, Stokes S, Hull KG. 2013. Novel topoisomerase inhibitors: microbiological characterization and in vivo efficacy of pyrimidines. Int. J. Antimicrob. Agents 41:363-371. http://dx.doi.org/10.1016/j .ijantimicag.2012.12.001.
42. Sherer BA, Hull K, Green O, Basarab G, Hauck S, Hill P, Loch JT, III, Mullen G, Bist S, Bryant J, Boriack-Sjodin A, Read J, DeGrace N, Uria-Nickelsen M, Illingworth RN, Eakin AE. 2011. Pyrrolamide DNA gyrase inhibitors: optimization of antibacterial activity and efficacy. Bioorg. Med. Chem. Lett. 21:7416-7420. http://dx.doi.org/10.1016/j .bmcl.2011.10.010.
43. Basarab GS, Manchester JI, Bist S, Boriack-Sjodin PA, Dangel B, Illingworth R, Sherer BA, Sriram S, Uria-Nickelsen M, Eakin AE. 2013. Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents. J. Med. Chem. 56:8712-8735. http://dx.doi.org/10.1021/ jm401208b.
44. Stokes SS, Gowravaram M, Huynh H, Lu M, Mullen GB, Chen B, Albert R, O'Shea TJ, Rooney MT, Hu H, Newman JV, Mills SD. 2011. Discovery of bacterial NAD-dependent DNAligase inhibitors: optimization of antibacterial activity. Bioorg. Med. Chem. Lett. 21:4556-4560. http: //dx.doi.org/10.1016/j.bmcl.2011.05.128.
45. Stokes SS, Gowravaram M, Huynh H, Lu M, Mullen GB, Chen B, Albert R, O'Shea TJ, Rooney MT, Hu H, Newman JV, Mills SD. 2012. Discovery of bacterial NAD-dependent DNA ligase inhibitors: improvements in clearance of adenosine series. Bioorg. Med. Chem. Lett. 22:85-89 http://dx.doi.org/10.1016/j.bmcl.2011.11.071
46. Martínez-Botella G, Loch JT, Green OM, Kawatkar SP, Olivier NB, Boriack-Sjodin PA, Keating TA. 2013. Sulfonylpiperidines as novel, antibacterial inhibitors of Gram-positive thymidylate kinase (TMK). Bioorg. Med. Chem. Lett. 23:169-173. http://dx.doi.org/10.1016/j.bmcl.2012.10 .128.
47. Martínez-Botella G, Breen JN, Duffy JES, Dumas J, Geng B, Gowers IK, Green OM, Guler S, Hentemann MF, Hernandez-Juan FA, Joseph- McCarthy D, Kawatkar S, Larsen NA, Lazari O, Loch JT, Macritchie JA, McKenzie AR, Newman JV, Olivier NB, Otterson LG, Owens AP, Read J, Sheppard DW, Keating TA. 2012. Discovery of selective and potent inhibitors of Gram-positive bacterial thymidylate kinase (TMK). J. Med. Chem. 55:10010-10021. http://dx.doi.org/10.1021/jm3011806.
48. Sugino A, Higgins NP, Brown PO, Peebles CL, Cozzarelli NR. 1978. Energy coupling in DNA gyrase and the mechanism of action of novobiocin. Proc. Natl. Acad. Sci. U. S. A. 75:4838-4842. http://dx.doi.org/10 .1073/pnas.75.10.4838.
49. Jacoby GA. 2005. Mechanisms of resistance to quinolones. Clin. Infect. Dis. 41:S120-S126. http://dx.doi.org/10.1086/428052.
50. Cesaro A, Bettoni RRD, Lascols C, Merens A, Soussy CJ, Cambau E. 2008. Low selection of topoisomerase mutants from strains of Escherichia coli harbouring plasmid-borne qnr genes. J. Antimicrob. Chemother. 61: 1007-1015. http://dx.doi.org/10.1093/jac/dkn077.
51. Shapiro AB, Jahic H, Prasad S, Ehmann D, Thresher J, Gao N, Hajec L. 2010. A homogeneous, high-throughput fluorescence anisotropy-based DNA supercoiling assay. J. Biomol. Screen. 15:1088-1098. http://dx.doi .org/10.1177/1087057110378624.
52. Bryskier A (ed). 2005. Antimicrobial agents. Antibacterials and antifungals. ASM Press, Washington, DC.
53. Zhang J-H, Chung TDY, Oldenburg KR. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4:67-73. http://dx.doi.org/10.1177 /108705719900400206.